13 February 2024
Belluscura plc
("Belluscura" or the "Company")
Belluscura announces implementation of distribution agreement with Sunset HealthCare Solutions
New Vice President of North American Sales
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces a new partnership with Sunset HealthCare Solutions ("Sunset Healthcare") and the promotion of Konstantin Grey to Vice President of North American Sales.
Sunset HealthCare is a Chicago-based manufacturer and distributor of Home Medical Equipment ("HME") supplies offering an extensive range of quality HME products, innovative solutions and specialised product support. It partners with over 1,600 healthcare businesses, serving all of the United States alongside key international accounts. Sunset Healthcare has a network of sales representatives extending across the US and in 150 countries around the globe.
Under the distribution agreement, Sunset HealthCare will offer the X-PLORĀ® portable oxygen concentrator ("POC") to over 1,600 customers. It is intended that the agreement will be extended to also include distribution of the award winning DISCOV-R? POC in Q2 2024 when the product becomes available to Durable Medical Equipment ("DME") suppliers.
Belluscura also announces that Konstantin Grey has been appointed Vice President of North American Sales. Having joined Belluscura in July 2023, Konstantin has been responsible for the creation and launch of Belluscura's direct to consumer sales force and website, which has seen strong growth in sales and gross margins since its launch last year. He also successfully launched our unique direct to consumer leasing program and has been instrumental in driving this new partnership with Sunset HealthCare, as well as a healthy pipeline of further opportunities. Konstantin has 15 years of experience in the DME industry, including having founded and subsequently sold his own DME company.
Robert Rauker, Chief Executive Officer, Belluscura plc, said:
"We welcome the new partnership with Sunset HealthCare Solutions, which will provide over 1,600 healthcare businesses with access to our innovative products through a trusted, industry leader. This agreement significantly expands our distribution network."
PJ Ruflin, VP Business Development, Sunset Healthcare Solutions, stated:
"Sunset Healthcare Solutions is committed to finding great products and partners to support our customers and their patients. Our partnership with Belluscura offers a unique opportunity to bring meaningful innovation and support to the market at a critical time."
Bob Fary, Senior Vice President of Global Sales, commented:
"Konstantin has been a tremendous asset since joining Belluscura, as demonstrated by his ability to bring on partners like Sunset Healthcare Solutions. In his new role as VP of North America, Konstantin is set to further drive Belluscura's mission of enhancing patient quality of life through innovative, accessible healthcare solutions. We look forward to building on our success to date as we launch our next generation molecular sieve technology and DISCOV-R."
END
For further information, please contact:
Belluscura plc | www.belluscura.com |
Robert Rauker, Chief Executive Officer | via MHP |
Simon Neicheril, Chief Financial Officer | |
| |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin / Jade Bayat | |
| |
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
James Serjeant / Nicholas Chambers | |
| |
MHP Communications (Financial PR and Investor Relations) | Tel: +44 (0)20 3128 8100 / +44 7884 494112 |
Katie Hunt / Matthew Taylor | Email: belluscura@mhpgroup.com |
| |
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.